RESUMEN
BACKGROUND: One of the most prevalent conditions in Western societies is gastroesophageal reflux disease (GERD). In Switzerland, the standard treatment for GERD is proton pump inhibitor (PPI)-based medical management, but surgical options such as Nissen fundoplication and magnetic sphincter augmentation (MSA) are available. RefluxStop is a novel device that offers an alternative solution. The purpose of this report is to evaluate the cost-effectiveness of RefluxStop compared to PPIs and existing surgical treatments. METHODS: A model (Markov) was developed using the Swiss healthcare payer perspective with a lifetime horizon, 1-month cycle length, and a 3% annual discount rate for costs and benefits. Adverse events specific to treatment arms were incorporated, and benefits were measured in quality-adjusted life-years (QALYs). Clinical efficacy data for RefluxStop was obtained from its CE mark study, and comparator treatments were based on published literature. Deterministic and probabilistic sensitivity analyses were used to explore uncertainty. Since there are no head-to-head studies between RefluxStop and PPI therapy, Nissen fundoplication, or MSA, a limitation of this study is the use of naïve, indirect comparison of clinical effectiveness between the studied treatment options. RESULTS: Higher QALYs and lower costs were provided by RefluxStop compared to Nissen fundoplication and the MSA system. The incremental cost-effectiveness ratio (ICER) for RefluxStop was CHF 2,116 in comparison to PPI-based medical management. At a cost-effectiveness threshold of CHF 100,000 per QALY gained, the probability of RefluxStop being cost-effective was high, with probabilities of 100%, 97%, and 100% against PPI-based medical management, Nissen fundoplication, and MSA, respectively. The robustness of the analysis was provided by deterministic and probabilistic sensitivity analyses. CONCLUSION: This cost-effectiveness analysis demonstrates that there is a high likelihood of RefluxStop being a cost-effective treatment modality in adults with GERD when compared with other treatment options available in Switzerland.
Gastroesophageal reflux disease (GERD) is one of the most prevalent conditions in Western societies. Standard treatment in Switzerland entails proton pump inhibitor (PPI)-based medical management or surgical options (i.e., Nissen fundoplication and magnetic sphincter augmentation [MSA]) in selected cases. RefluxStop is a new technology indicated for the surgical treatment of GERD that restores the normal anatomy of the anti-reflux barrier. The clinical benefits and monetary costs of RefluxStop must be weighed against available treatment options to determine the role of this new technology in Switzerland. Cost-effectiveness analyses compare the relative costs and clinical outcomes of disease management when pursuing different paths in the patient journey landscape, as measured by quality-adjusted life-years (QALYs). In the present study, RefluxStop in comparison to Nissen fundoplication, and MSA, provided higher QALYs and lower costs. Against PPI therapy, the costs were slightly higher but the QALYs were also higher, generating a favourable Incremental cost-effectiveness ratio. Furthermore, at the cost-effectiveness threshold of CHF 100,000 per QALY gained, RefluxStop was highly likely to be cost-effective in comparison to PPI therapy, Nissen fundoplication, and MSA with probabilities of 100%, 97%, and 100%, respectively. Ultimately, this cost-effectiveness analysis showed that RefluxStop has a high likelihood of cost-effectiveness as a GERD treatment in Switzerland against other treatment options, with results being robust even with uncertainties considered in additional sensitivity analyses.
Asunto(s)
Análisis Costo-Beneficio , Fundoplicación , Reflujo Gastroesofágico , Cadenas de Markov , Inhibidores de la Bomba de Protones , Años de Vida Ajustados por Calidad de Vida , Humanos , Suiza , Inhibidores de la Bomba de Protones/uso terapéutico , Inhibidores de la Bomba de Protones/economía , Fundoplicación/métodos , Fundoplicación/economía , Femenino , Masculino , Persona de Mediana Edad , Adulto , AncianoRESUMEN
INTRODUCTION: The Reference Drug Program (RDP) was established to steer patients toward equally safe and cost-effective medication under British Columbia's public drug coverage. Each RDP class covers at least one reference drug, and non-reference drugs are reimbursed up to the cost of the reference drug. In 2016, the RDP updated to include proton pump inhibitors (PPIs). This study evaluated the impact on drug expenditures, prescription patterns, and health services utilization. METHODS: We identified a cohort of individuals covered by Fair Pharmacare who used PPIs, and a control group of H2 Blockers users. We used interrupted time series analysis on administrative data from June 2014 to December 2019 on the following outcomes: new users, day supply, expenditures, drug costs, reference drug use, and physician visits and costs. RESULTS: The RDP had little impact on overall PPI use patterns. We did not observe any changes in reference drug uptake, new users, physician visits, cost-savings, or significant changes to days supplied post-policy. Cost expenditure results were likely biased due to co-occurring changes to drug prices. CONCLUSION: Inclusion of PPIs to the RDP saw no cost-savings for the provincial drug program and had little impact on prescribing patterns. Overall, our findings are consistent with existing evidence that the RDP is safe for similar therapeutic alternatives, but the impact on PPI costs remains unclear.
Asunto(s)
Costos de los Medicamentos , Pautas de la Práctica en Medicina , Inhibidores de la Bomba de Protones , Inhibidores de la Bomba de Protones/uso terapéutico , Inhibidores de la Bomba de Protones/economía , Humanos , Colombia Británica , Pautas de la Práctica en Medicina/estadística & datos numéricos , Costos de los Medicamentos/estadística & datos numéricos , Masculino , Femenino , Aceptación de la Atención de Salud/estadística & datos numéricos , Persona de Mediana Edad , Gastos en Salud/estadística & datos numéricos , Análisis de Series de Tiempo InterrumpidoRESUMEN
INTRODUCTION: Proton pump inhibitors (PPIs) constitute a widely utilized pharmaceutical class, frequently associated with notable instances of therapeutic inappropriateness. Such patterns of misuse not only contribute to elevated healthcare expenditure, but may also exacerbate clinical conditions in certain patients. METHODS: A comprehensive analysis was conducted between 2019 and 2023 to assess all prescriptions dispensed using the Anatomical, Therapeutic and Chemical (ATC) classification system, which allowed trends among primary PPIs to be visualized. This was achieved by calculating the defined daily dose (DDD) and then defining the total expenditure incurred on these drugs. RESULTS: With regard to the prescription of PPIs, an upward trend in consumption was observed with a decreasing expenditure, due to the phenomena of drug generics and increased competition between pharmaceutical companies, ranging from 9,512,481.22 in the first six months of 2019 to 8,509,820.80 in the first six months of 2023. From 2019 to 2023, consumption increased by approximately 3 million DDDs for a total ranging from 18,483,167.59 DDDs to 21,480,871.00 DDDs. Pantoprazole and esomeprazole, the most expensive drugs compared to omeprazole, rabeprazole and lansoprazole, accounted for 61.4% of therapies in the first six months of 2023, up from 2019, where these two drugs were prescribed 54.9%. CONCLUSION: Within this analysis, we provide an illustrative representation of the prescribing trends for PPIs within a European context. Omeprazole, rabeprazole and lansoprazole appear to be the cheapest drugs compared to pantoprazole and esomeprazole. However, the results show that the most widely used PPIs, despite their therapeutic equivalence, are precisely the high-cost ones, thus generating higher expenditure for central governments.
Asunto(s)
Gastos en Salud , Lansoprazol , Pantoprazol , Inhibidores de la Bomba de Protones , Inhibidores de la Bomba de Protones/economía , Inhibidores de la Bomba de Protones/uso terapéutico , Humanos , Lansoprazol/economía , Lansoprazol/administración & dosificación , Gastos en Salud/tendencias , Gastos en Salud/estadística & datos numéricos , Omeprazol/economía , Omeprazol/uso terapéutico , Esomeprazol/economía , Rabeprazol/economía , Rabeprazol/administración & dosificación , Costos de los Medicamentos/tendencias , Costos de los Medicamentos/estadística & datos numéricos , Medicamentos Genéricos/economía , Utilización de Medicamentos/tendencias , Utilización de Medicamentos/estadística & datos numéricosRESUMEN
ABSTRACT: The purpose of this study was to evaluate the clinical outcomes, including patient prognosis and medication expense, of proton pump inhibitors administered by high-dose continuous infusion (HDC, 80âmg loading dose, then 8âmg/h for 72âhours) or non-high-dose intermittent infusion (NHDI, 40âmg qd or 40âmg q12âh, for 3âdays) regimens in high-risk patients with bleeding peptic ulcers.In this retrospective cohort study, patients with peptic ulcers and endoscopic hemostasis between January, 2013 and December, 2015 were included. The primary endpoints were rebleeding and mortality rates within 7âdays. The secondary endpoints were length of stay (LOS), transfusion units of packed red blood cells (PRBCs), and the number needed to treat.A total of 335 patients met the inclusion criteria during the 3-year follow-up period. The cumulative incidence of rebleeding within 7âdays was 20.4% and 11.2% in the HDC and NHDI groups, respectively, with a significant difference (Pâ=â.021). The mortality rate was 12.1% and 7.3% in the HDC and NHDI groups, respectively, with no significant difference (Pâ=â.136). Univariate Cox proportional hazards model analysis showed that the risk of rebleeding within 7âdays in the HDC group was higher than that in the NHDI group. The hazard ratio for HDC vs. NHDI was 1.93 (Pâ=â.021). There were significant differences in LOS (Pâ=â.034) and PRBC units (Pâ=â.005) for risk of rebleeding within 7âdays, as well as in transfusion units of PRBCs for mortality rate analysis (pâ<â0.001), between the HDC and NHDI groups. The results showed that the NHDI regimen could reduce the risk of rebleeding within 7âdays in 1 of 11 patients (number needed to treatâ=â11) and could reduce medication cost by US$ 400 to 800.The NHDI regimen showed a lower risk of rebleeding within 7âdays, shorter LOS, and fewer PRBC units than that of the HDC regimen. Receiving NHDI has better cost-effective outcomes than that of HDC for patients with high-risk bleeding peptic ulcers.
Asunto(s)
Anemia Ferropénica , Hemostasis Endoscópica , Inhibidores de la Bomba de Protones/economía , Anciano , Análisis Costo-Beneficio , Femenino , Humanos , Masculino , Persona de Mediana Edad , Úlcera Péptica/complicaciones , Úlcera Péptica/tratamiento farmacológico , Úlcera Péptica Hemorrágica/tratamiento farmacológico , Inhibidores de la Bomba de Protones/efectos adversos , Recurrencia , Estudios Retrospectivos , Resultado del TratamientoRESUMEN
To evaluate the efficacy and economics of different proton pump inhibitors (PPIs) combined with bismuth quadruple regimens for Helicobacter pylori (Hp) eradication, a retrospective analysis method was used to collect Hp-positive patients who were treated with a bismuth-containing quadruple regimen (PPIs + amoxicillin + furazolidone + colloid pectin bismuth) from the outpatient department of gastroenterology in our hospital from January to June 2017. A total of 1410 patients were included in the study and divided into four groups according to different PPIs: group A (pantoprazole sodium enteric-coated capsules, 352 cases), group B (esomeprazole magnesium enteric-coated tablets, 462 cases), group C (pantoprazole sodium enteric-coated tablets, 392 cases) and group D (rabeprazole sodium enteric-coated tablets, 204 cases). The eradication rate of Hp and cost-saving in each group were then compared. There were no significant differences of gender (P = 0.526) and age (P = 0.366) between each Hp treatment regimen. The eradication rates of groups A, B, C and D were 91.48%, 89.83%, 86.73% and 90.69%, respectively. No statistical differences of Hp eradication rates were observed between each group yet (P > 0.05). However, the cost of group A was the lowest. In the present study, the Hp eradication rates between different PPIs regimens were similar in treating Hp infection. Nevertheless, the point in favor of pantoprazole capsules is the slightly higher Hp eradication rate and lower drug cost than other PPIs, which provides a significant evidence for the clinical medication decision in treating Hp infection.
Asunto(s)
Bismuto/farmacología , Infecciones por Helicobacter/tratamiento farmacológico , Inhibidores de la Bomba de Protones/farmacología , Adulto , Amoxicilina/economía , Amoxicilina/farmacología , Antibacterianos/economía , Antibacterianos/farmacología , Pruebas Respiratorias , China , Costos de los Medicamentos , Quimioterapia Combinada , Femenino , Furazolidona/economía , Furazolidona/farmacología , Humanos , Masculino , Persona de Mediana Edad , Inhibidores de la Bomba de Protones/economía , Estudios Retrospectivos , Resultado del TratamientoRESUMEN
RATIONALE AND OBJECTIVE: Proton pump inhibitor (PPI) is one of the most widely prescribed medicines and commonly used in gastric related disorders and there is a huge need to analyze the irrational use of PPI in a country like India. The present study was designed to describe the rational drug use and cost comparison analysis of PPI in a rural tertiary care hospital. METHODOLOGY: A prospective observational study was performed among 253 inpatients for a period of 9 months after getting ethical approval. Those who received the PPIs for any of its indications were included in the study without any gender or age restriction. US FDA guidelines were used to analyse the appropriateness of the drug use and cost comparison analysis of the branded versus generic PPIs was also performed. FINDINGS: Among the 253 inpatients, the majority (62%) were male and the mean age was 46±19 years. Mean hospital stay and the number of drugs in prescription were found to be 4.0 ± 1days 4.39 ±1.16 items, respectively. Pantoprazole (76%) was the most prescribed PPI even though the majority (57%) of the patients treated outside the FDA approved indication. Drug interaction has been reported in 14% and ADR in 9% of the population. The average cost of hospital stay estimated as 207.96+149.57 INR, and potential cost saving of INR 41582 was observed with generic replacement. CONCLUSION: The study inferred irrational drug use of PPI still prevalent, that too without considering the economic impact of it on general populations. Healthcare practitioners should be aware and cautious while prescribing the PPI to identify the actual need and to choose the most cost-effective alternative 1.
Asunto(s)
Costos y Análisis de Costo , Utilización de Medicamentos/economía , Inhibidores de la Bomba de Protones/economía , Inhibidores de la Bomba de Protones/uso terapéutico , Adulto , Anciano , Femenino , Humanos , Masculino , Persona de Mediana Edad , Pautas de la Práctica en Medicina/normas , Estudios Prospectivos , Atención Terciaria de Salud , Adulto JovenRESUMEN
PURPOSE: The study's aim was to compare the use of proton pump inhibitors (PPIs), histamine 2-receptor antagonists (H2RAs) and mucoprotective medicines (MPs) used for gastric acid-related disorders (GARD) in Australia and South Korea (Korea) from 2004 to 2017. METHODS: Prescription data for PPIs, H2RAs and MPs for Australian outpatients were extracted from the Australian Statistics on Medicines annual reports, with dose-specific and expenditure data obtained from Medicare. Similar data were obtained from Korean National Health Insurance Service claims data. We analysed the volume and expenditure of medicines use annually using the defined daily dose per 1,000 population per day. We calculated which medicines accounted for 90% of use and estimated the proportions of use for low- and high-dose PPIs. RESULTS: While total utilisation for GARD medicines increased over time in both countries, patterns of use differed. Overall, use was somewhat higher in Australia but increased more rapidly in Korea. PPIs were used more extensively in Australia, while more MPs and H2RAs were used in Korea. Expenditure and use of low-dose PPIs is escalating in Korea. CONCLUSION: There were substantial differences in the use of GARD medicines in Australia and Korea over 14 years. Both countries face similar challenges to promote rational medicines use and contain medical care costs. The discrepant prescribing patterns can be attributed to differences in healthcare systems, pharmaceutical policies and demographics. This study provides a baseline to influence more rational use of these medicines. It provides insight into medicines policies for other countries that face similar challenges.
Asunto(s)
Antiulcerosos/administración & dosificación , Utilización de Medicamentos/estadística & datos numéricos , Dispepsia/tratamiento farmacológico , Ácido Gástrico/metabolismo , Antagonistas de los Receptores H2 de la Histamina/administración & dosificación , Inhibidores de la Bomba de Protones/administración & dosificación , Antiulcerosos/economía , Antiulcerosos/uso terapéutico , Australia , Utilización de Medicamentos/economía , Dispepsia/metabolismo , Gastos en Salud , Antagonistas de los Receptores H2 de la Histamina/economía , Antagonistas de los Receptores H2 de la Histamina/uso terapéutico , Humanos , Programas Nacionales de Salud , Pautas de la Práctica en Medicina/estadística & datos numéricos , Inhibidores de la Bomba de Protones/economía , Inhibidores de la Bomba de Protones/uso terapéutico , República de CoreaRESUMEN
BACKGROUND: In accordance with current guidelines, proton pump inhibitors (PPIs) are now generally prescribed as a protective co-medication in patients taking non-steroidal anti-inflammatory drugs (NSAIDs) or low-dose acetylsalicylic acid (LDASA). However, less attention is paid to the corresponding discontinuation of a PPI after cessation of NSAID or LDASA treatment. OBJECTIVE: The aim of this study was to assess the extent of inappropriate PPI use, as the proportion of patients who started a PPI as a protective co-medication but continued using these drugs after cessation of NSAID and LDASA treatment. We also sought to estimate the potential cost savings and effect gains of discontinuing inappropriate PPI use and the resulting decrease in adverse effects and their detrimental consequences. METHODS: Pharmacy dispensing data were used to map inappropriate PPI use in 2014 for community-dwelling patients. Strategies with or without PPI continuation were compared in the cost-utility analysis for a time horizon of 5 years from a healthcare perspective. Subsequently, incremental costs and effects (quality-adjusted life-years) were estimated with a Markov model. RESULTS: Related to NSAID and LDASA treatment, 11.0% and 5%, respectively, of the PPI users were found to inappropriately continue PPI co-treatment. Discontinuation in 71- to 80-year-old patients suggested cost savings of 170.46 (95% confidence interval 75-282) at a 0.003 (95% confidence interval 0.001-0.005) quality-adjusted life-year increase. The total budget impact of stopping inappropriate PPI use related to NSAID/LDASA treatment in the Netherlands would amount to almost 1,050,000 after 1 year. Correspondingly, successful interventions to stop a patient's inappropriate use would cost up to 29 and probably would pay for themselves in the following years. CONCLUSIONS: A substantial number of patients inappropriately continue to use a PPI after cessation of NSAID or LDASA treatment. Because adverse effects and their detrimental consequences are avoided, interventions to stop inappropriate PPI use, particularly in older patients, are likely to pay for themselves.
Asunto(s)
Antiinflamatorios no Esteroideos/efectos adversos , Aspirina/efectos adversos , Inhibidores de la Bomba de Protones/efectos adversos , Anciano , Anciano de 80 o más Años , Análisis Costo-Beneficio , Humanos , Prescripción Inadecuada , Persona de Mediana Edad , Inhibidores de la Bomba de Protones/economíaAsunto(s)
Antiulcerosos/uso terapéutico , Úlcera Péptica/prevención & control , Úlcera Péptica/terapia , Mejoramiento de la Calidad , Estrés Fisiológico , Estrés Psicológico/complicaciones , Enfermedad Aguda , Adulto , Anciano , Antiulcerosos/economía , Australia , Humanos , Unidades de Cuidados Intensivos , Persona de Mediana Edad , Educación del Paciente como Asunto , Úlcera Péptica/economía , Farmacéuticos , Estudios Prospectivos , Inhibidores de la Bomba de Protones/economía , Inhibidores de la Bomba de Protones/uso terapéuticoRESUMEN
BACKGROUND: Gastroesophageal reflux disease (GERD) can be treated using a vonoprazan-first strategy (first-line treatment with vonoprazan), or esomeprazole-first/rabeprazole-first strategies (first-line treatment with proton-pump inhibitors [PPIs], esomeprazole/rabeprazole, followed by a switch to vonoprazan). This cost-utility analysis used long-term simulation modeling to evaluate the cost-effectiveness of a vonoprazan-first strategy compared with the esomeprazole-first and rabeprazole-first strategies. METHODS: A Markov simulation model was developed to evaluate the cost-effectiveness of vonoprazan-first, esomeprazole-first, and rabeprazole-first strategies, comprising healing and maintenance therapies, over 5 years (4-week cycles). Healing therapy began with the administration of a normal dose of drug per real-world practice. If patients were not healed endoscopically, either a longer duration of healing therapy was provided (vonoprazan), the dose was increased (rabeprazole), or patients were switched to vonoprazan (immediately for esomeprazole, and after dose-escalation for rabeprazole, respectively). Healed patients received maintenance (lower/same dose as healing therapy). Recurrence resulted in re-challenge with healing therapy. Transition probabilities were derived from the results of indirect comparisons (network meta-analysis) and costs calculated from the Japanese payer perspective. Outcomes were defined as quality-adjusted life years (QALYs), with utilities based on published values. RESULTS: Expected costs of the vonoprazan-, esomeprazole-, and rabeprazole-first strategies were ¥36,194, ¥76,719, and ¥41,105, respectively, over 5 years. QALY gains for vonoprazan-first strategy versus the esomeprazole- and rabeprazole-first strategies were 0.014 and 0.003, respectively. Both estimated incremental cost-effectiveness ratios were dominant and robust to two sensitivity analyses. CONCLUSIONS: Vonoprazan-first strategy increased QALYs and appeared to be cost-effective for GERD patients compared with the esomeprazole- or rabeprazole-first strategies.
Asunto(s)
Esomeprazol/administración & dosificación , Reflujo Gastroesofágico/tratamiento farmacológico , Pirroles/administración & dosificación , Rabeprazol/administración & dosificación , Sulfonamidas/administración & dosificación , Simulación por Computador , Análisis Costo-Beneficio , Esomeprazol/economía , Reflujo Gastroesofágico/economía , Humanos , Japón , Cadenas de Markov , Inhibidores de la Bomba de Protones/administración & dosificación , Inhibidores de la Bomba de Protones/economía , Pirroles/economía , Años de Vida Ajustados por Calidad de Vida , Rabeprazol/economía , Recurrencia , Sulfonamidas/economía , Factores de Tiempo , Resultado del TratamientoRESUMEN
OBJECTIVE: The high pharmaceutical consumption requires establishing improvement measures with the collaboration of all the agents involved. The objective of the study was to analyze the pharmaceutical expenditure generated by prescriptions made by physicians working in a primary care area and assess its relationship with the quality indicators of the prescription. METHODS: The prescriptions of 200 family physicians of the Basque Health Service Araba Countyand dispensed by the community pharmacies between 2009 and 2016 were studied. The variables evaluated retrospectively corresponded to the quality indicators of the pharmaceutical prescription included in the Contract-Program of the Basque Department Health of 2016. Prediction models were developed using linear regression and binary logistic regression analysis. RESULTS: The main factors which increased the pharmaceutical expenditure per person were: the use of novel drugs which do not offer therapeutic improvements, the proportion of pensioners, the use of statins and the use of antiulcer the proton pump inhibitors (PPI). On the contrary, the factors that reduced this expense were: the seniority in the medical position, the physician job stability and the prescription quality index. The profile of the doctor who generated the greatest expense of pharmaceutical prescription was mainly that of a professional who was responsible for a high percentage of pensioners, prescribed a high amount of inhibitors of the enzyme angiotensin converting enzyme inhibitors (ACEI), prescribed a high amount of first level non-steroidal anti-inflammatory drugs (NSAIDs) and also showed high use of antiulcer PPI. CONCLUSIONS: There is a statistically significant correlation between physicians who generate lower pharmaceutical expenditure and have a higher quality of prescription. The most influencing factors in the pharmaceutical expenditure are a high percentage of pensioners in the medical quota, the use of novel drugs that do not provide therapeutic improvements and the prescription of statins and anti-ulcer PPI drugs.
OBJETIVO: El elevado consumo farmacéutico requiere establecer medidas de mejora con la colaboración de todos los agentes implicados. El objetivo del estudio fue analizar el gasto farmacéutico generado por las recetas prescritas por los médicos que trabajan en un área de atención primaria y evaluar su relación con los indicadores de calidad de la prescripción. METODOS: Se estudiaron las prescripciones de 200 médicos de familia de la Comarca Araba de Osakidetza y dispensadas por las oficinas de farmacia entre los años 2009 y 2016. Las variables evaluadas retrospectivamente correspondieron a los indicadores de calidad de la prescripción farmacéutica recogidos en el Contrato-Programa del Departamento de Salud del 2016. Se elaboraron modelos de predicción mediante técnicas de regresión lineal y logística binaria. RESULTADOS: Los principales factores que aumentaron el gasto farmacéutico por persona fueron: el uso de medicamentos novedosos que no ofrecen mejoras terapéuticas, la proporción de pensionistas, el uso de estatinas y el uso de antiulcerosos inhibidores de la bomba de protones (IBP). Por el contrario, los factores que redujeron este gasto fueron: la antigüedad en la plaza médica, la estabilidad laboral e el índice de calidad de prescripción. El perfil del médico que generó mayor gasto de prescripción farmacéutica fue principalmente el de un profesional que tenía a su cargo un elevado porcentaje de pensionistas, recetaba una cantidad elevada de inhibidores del enzima convertidor de angiotensina (IECA), prescribía una elevada cantidad de antiinflamatorios no esteroideos (AINE) de primer nivel e igualmente tenía un elevado uso de antiulcerosos IBP. CONCLUSIONES: Existe una correlación estadísticamente significativa entre los médicos que generan un menor gasto farmacéutico y presentan mayor calidad de la prescripción. Los factores que más influyen en el gasto farmacéutico son un elevado porcentaje de pensionistas en el cupo médico, el uso de medicamentos novedosos que no aportan mejoras terapéuticas y la prescripción de estatinas y de antiulcerosos IBP.
Asunto(s)
Prescripciones de Medicamentos/economía , Gastos en Salud/normas , Atención Primaria de Salud/normas , Calidad de la Atención de Salud , Anciano , Antiinflamatorios no Esteroideos/economía , Antiulcerosos/economía , Femenino , Humanos , Inhibidores de Hidroximetilglutaril-CoA Reductasas/economía , Modelos Logísticos , Masculino , Persona de Mediana Edad , Farmacias , Atención Primaria de Salud/economía , Inhibidores de la Bomba de Protones/economía , Análisis de Regresión , Estudios Retrospectivos , España/epidemiologíaRESUMEN
BACKGROUND: Helicobacter pylori is involved in many upper gastrointestinal diseases such as peptic ulcers and gastric cancers. In this study, we compared the cost-effectiveness of lansoprazole and vonoprazan in H. pylori eradication therapy and examined the effectiveness of pharmacist-managed outpatient clinics. METHODS: We investigated the efficacy and cost-effectiveness of pharmacist-managed outpatient clinics in H. pylori eradication therapy at our hospital from January 2015 to December 2017. The subjects were classified into three groups: lansoprazole group; vonoprazan group; and the medication instruction group, which received instructions at the pharmacist-managed outpatient clinics (intervention group). We examined the eradication rate and cost-effectiveness ratio of each group. RESULTS: The eradication rate of primary eradication therapy was 75.2% in the lansoprazole group, 87.8% in the vonoprazan group and 91.4% in the intervention group. When mental component summary was used as quality of life score, cost-effectiveness ratio was 224.7 yen in lansoprazole group, 223.9 yen in vonoprazan group and 222.2 yen in intervention group. Setting up pharmacist-managed outpatient clinics increases the pharmacist labour cost necessary for eradication therapy. However, if the medication instructions provided by the pharmacist can lead to improved disinfection efficiency, improvement in cost efficiency can be expected. CONCLUSION: Although medication instructions provided at the pharmacist-managed outpatient clinics incur additional labour costs, they improve patient quality of life as well as disinfection rate in H. pylori eradication therapy. Therefore, pharmacist-managed outpatient clinics are useful from the viewpoint of pharmacoeconomics.
Asunto(s)
Instituciones de Atención Ambulatoria/economía , Análisis Costo-Beneficio , Infecciones por Helicobacter/tratamiento farmacológico , Helicobacter pylori , Lansoprazol/uso terapéutico , Inhibidores de la Bomba de Protones/uso terapéutico , Pirroles/uso terapéutico , Sulfonamidas/uso terapéutico , Adulto , Anciano , Instituciones de Atención Ambulatoria/organización & administración , Costos de los Medicamentos , Femenino , Infecciones por Helicobacter/economía , Humanos , Japón , Lansoprazol/economía , Masculino , Persona de Mediana Edad , Farmacéuticos/economía , Inhibidores de la Bomba de Protones/economía , Pirroles/economía , Calidad de Vida , Sulfonamidas/economía , Resultado del TratamientoRESUMEN
OBJECTIVES: To determine the economic impact of three drugs commonly involved in potentially inappropriate prescribing (PIP) in adults aged ≥65 years, including their adverse effects (AEs): long-term use of non-steroidal anti-inflammatory drugs (NSAIDs), benzodiazepines and proton pump inhibitors (PPIs) at maximal dose; to assess cost-effectiveness of potential interventions to reduce PIP of each drug. DESIGN: Cost-utility analysis. We developed Markov models incorporating the AEs of each PIP, populated with published estimates of probabilities, health system costs (in 2014 euro) and utilities. PARTICIPANTS: A hypothetical cohort of 65 year olds analysed over 35 1-year cycles with discounting at 5% per year. OUTCOME MEASURES: Incremental cost, quality-adjusted life years (QALYs) and incremental cost-effectiveness ratios with 95% credible intervals (CIs, generated in probabilistic sensitivity analysis) between each PIP and an appropriate alternative strategy. Models were then used to evaluate the cost-effectiveness of potential interventions to reduce PIP for each of the three drug classes. RESULTS: All three PIP drugs and their AEs are associated with greater cost and fewer QALYs compared with alternatives. The largest reduction in QALYs and incremental cost was for benzodiazepines compared with no sedative medication (3470, 95% CI 2434 to 5001; -0.07 QALYs, 95% CI -0.089 to -0.047), followed by NSAIDs relative to paracetamol (806, 95% CI 415 and 1346; -0.07 QALYs, 95% CI -0.131 to -0.026), and maximal dose PPIs compared with maintenance dose PPIs (989, 95% CI -69 and 2127; -0.01 QALYs, 95% CI -0.029 to 0.003). For interventions to reduce PIP, at a willingness-to-pay of 45 000 per QALY, targeting NSAIDs would be cost-effective up to the highest intervention cost per person of 1971. For benzodiazepine and PPI interventions, the equivalent cost was 1480 and 831, respectively. CONCLUSIONS: Long-term benzodiazepine and NSAID prescribing are associated with significantly increased costs and reduced QALYs. Targeting inappropriate NSAID prescribing appears to be the most cost-effective PIP intervention.
Asunto(s)
Prescripción Inadecuada/economía , Prescripción Inadecuada/prevención & control , Pautas de la Práctica en Medicina/organización & administración , Atención Primaria de Salud/organización & administración , Anciano , Anciano de 80 o más Años , Antiinflamatorios no Esteroideos/efectos adversos , Antiinflamatorios no Esteroideos/economía , Benzodiazepinas/efectos adversos , Benzodiazepinas/economía , Estudios de Cohortes , Análisis Costo-Beneficio , Femenino , Humanos , Masculino , Cadenas de Markov , Administración del Tratamiento Farmacológico/organización & administración , Modelos Económicos , Pautas de la Práctica en Medicina/economía , Atención Primaria de Salud/economía , Inhibidores de la Bomba de Protones/efectos adversos , Inhibidores de la Bomba de Protones/economía , Años de Vida Ajustados por Calidad de VidaRESUMEN
This industry update covers the period from 1 to 31 October 2018 and is based on information sourced from company press releases, scientific literature, patents and various news websites. With the expiry in Europe of AbbVie's (IL, USA) principal patent on Humira this month, the first biosimilar versions of the drug have been launched. AstraZeneca (Cambridge, UK) announced that is has out-licensed two none core drugs to Grunenthal (Aachen, German), while Pfizer (NY, USA) announced the creation of a new company, set up in collaboration with Bain Capital (MA, USA) to exploit Pfizer's clinical and preclinical assets in the neuroscience field. In digital health, 23andMe (CA, USA) announced that the US FDA has authorized marketing of one of its consumer genetic tests, that assesses the genetic factors that affect drug metabolization, hence the safety and efficacy of some drugs. Novartis (Basel, Switzerland) continued to grow its activities in digital health with the creation of the Novartis Biome, an incubator and support program for early-stage companies in this area. Novartis also announced that it has filed applications in the EU and USA for the approval of siponimod, a drug targeting secondary progressive multiple sclerosis and Roche (Basel, Switzerland) gained FDA approval for an antiviral treatment for influenza. Janssen (Beerse, Belgium) announced it had won a label extension for its blood glucose-lowering drug, Invokana®, for the reduction of cardiovascular events in diabetes. Roche presented data at ECTRIMS, a major annual conference on multiple sclerosis (MS), held in Berlin, Germany this month (10-12 October 2018), showing the potential benefits of administering its drug, Ocrevus, earlier in the treatment pathway for MS compared with other standard treatment. At the same event, Celgene (NJ, USA) presented results from a survey that showed MS patients' concern around brain atrophy and cognitive loss in MS, highlighting that the disease has a neurodegenerative as well as an inflammatory component. Novartis also presented a significant amount of data supporting its marketed drugs as well as its development pipeline in the disease. This month, presentation of data from two studies at the American Academy of Ophthalmology annual meeting (27-30 October 2018, Chicago, IL, USA) further supporting the potential of eye scans in the early detection of Alzheimer's. A paper by a research team at the University of Rochester (NY, USA) demonstrated the feasibility of a new mechanism to transport drugs across the blood-brain barrier, which could help development more effective CNS drugs.
Asunto(s)
Biosimilares Farmacéuticos/economía , Industria Farmacéutica , Mercadotecnía/economía , Artritis Reumatoide/tratamiento farmacológico , Biosimilares Farmacéuticos/uso terapéutico , Aprobación de Drogas/economía , Regulación Gubernamental , Humanos , Inhibidores de la Bomba de Protones/economía , Inhibidores de la Bomba de Protones/uso terapéutico , Telemedicina , Úlcera/tratamiento farmacológico , Estados Unidos , United States Food and Drug AdministrationRESUMEN
OBJECTIVE: To characterize the association between industry payments and prescriptions of 2 brand-name proton-pump inhibitors (PPIs). STUDY DESIGN: Cross-sectional retrospective. SETTING: Physicians nationwide. SUBJECTS AND METHODS: We identified all physicians receiving industry payments for Dexilant and Nexium 2014-2015 from the Open Payments database. We linked this to records of prescriptions for PPIs paid for by Medicare Part D these same years and compared the proportion of prescriptions written for Dexilant and Nexium in industry-compensated vs nonindustry compensated physicians. The number and dollar amount of payments were associated with the rate of drug prescriptions. RESULTS: We identified 254,452 physicians prescribing PPIs; 8586 and 2766 physicians received industry payments for Dexilant and Nexium, respectively. A total of 5052 of 7876 (64%) physicians compensated for Dexilant prescribed Dexilant vs 39,778 of 246,571 (16%) noncompensated physicians ( P < .001). For Nexium, 2525 of 2654 (95%) compensated physicians prescribed Nexium, compared to 123,913 of 252,067 (49%) noncompensated physicians. For both Dexilant and Nexium, there was a significant correlation between the number (ρ = 0.22, P < .001 and ρ = 0.12, P < .001) and dollar amount (ρ = 0.22, P < .001 and ρ = 0.13, P < .001) of payments and the percentage of prescriptions written for the compensated drug. Industry payments for Nexium remained associated with rate of prescription even after generic esomeprazole became available. CONCLUSION: Both the number and dollar amount of industry payments were associated with increased prescriptions for both Dexilant and Nexium. Although unable to show causality, this study suggests that industry payments may increase physician prescriptions of costly, brand-name drugs.
Asunto(s)
Dexlansoprazol/administración & dosificación , Industria Farmacéutica/economía , Esomeprazol/administración & dosificación , Donaciones/ética , Pautas de la Práctica en Medicina/economía , Inhibidores de la Bomba de Protones/administración & dosificación , Conflicto de Intereses , Estudios Transversales , Dexlansoprazol/economía , Industria Farmacéutica/ética , Utilización de Medicamentos/estadística & datos numéricos , Esomeprazol/economía , Femenino , Humanos , Masculino , Medicare Part D/economía , Medicamentos bajo Prescripción/economía , Inhibidores de la Bomba de Protones/economía , Estudios Retrospectivos , Estadísticas no Paramétricas , Estados UnidosRESUMEN
OBJETIVO: El elevado consumo farmacéutico requiere establecer medidas de mejora con la colaboración de todos los agentes implicados. El objetivo del estudio fue analizar el gasto farmacéutico generado por las recetas prescritas por los médicos que trabajan en un área de atención primaria y evaluar su relación con los indicadores de calidad de la prescripción. MÉTODOS: Se estudiaron las prescripciones de 200 médicos de familia de la Comarca Araba de Osakidetza y dispensadas por las oficinas de farmacia entre los años 2009 y 2016. Las variables evaluadas retrospectivamente correspondieron a los indicadores de calidad de la prescripción farmacéutica recogidos en el Contrato-Programa del Departamento de Salud del 2016. Se elaboraron modelos de predicción mediante técnicas de regresión lineal y logística binaria. RESULTADOS: Los principales factores que aumentaron el gasto farmacéutico por persona fueron: el uso de medicamentos novedosos que no ofrecen mejoras terapéuticas, la proporción de pensionistas, el uso de estatinas y el uso de antiulcerosos inhibidores de la bomba de protones (IBP). Por el contrario, los factores que redujeron este gasto fueron: la antigüedad en la plaza médica, la estabilidad laboral e el índice de calidad de prescripción. El perfil del médico que generó mayor gasto de prescripción farmacéutica fue principalmente el de un profesional que tenía a su cargo un elevado porcentaje de pensionistas, recetaba una cantidad elevada de inhibidores del enzima convertidor de angiotensina (IECA), prescribía una elevada cantidad de antiinflamatorios no esteroideos (AINE) de primer nivel e igualmente tenía un elevado uso de antiulcerosos IBP. CONCLUSIONES: Existe una correlación estadísticamente significativa entre los médicos que generan un menor gasto farmacéutico y presentan mayor calidad de la prescripción. Los factores que más influyen en el gasto farmacéutico son un elevado porcentaje de pensionistas en el cupo médico, el uso de medicamentos novedosos que no aportan mejoras terapéuticas y la prescripción de estatinas y de antiulcerosos IBP
OBJECTIVE: The high pharmaceutical consumption requires establishing improvement measures with the collaboration of all the agents involved. The objective of the study was to analyze the pharmaceutical expenditure generated by prescriptions made by physicians working in a primary care area and assess its relationship with the quality indicators of the prescription. METHODS: The prescriptions of 200 family physicians of the Basque Health Service Araba Countyand dispensed by the community pharmacies between 2009 and 2016 were studied. The variables evaluated retrospectively corresponded to the quality indicators of the pharmaceutical prescription included in the Contract-Program of the Basque Department Health of 2016. Prediction models were developed using linear regression and binary logistic regression analysis. RESULTS: The main factors which increased the pharmaceutical expenditure per person were: the use of novel drugs which do not offer therapeutic improvements, the proportion of pensioners, the use of statins and the use of antiulcer the proton pump inhibitors (PPI). On the contrary, the factors that reduced this expense were: the seniority in the medical position, the physician job stability and the prescription quality index. The profile of the doctor who generated the greatest expense of pharmaceutical prescription was mainly that of a professional who was responsible for a high percentage of pensioners, prescribed a high amount of inhibitors of the enzyme angiotensin converting enzyme inhibitors (ACEI), prescribed a high amount of first level non-steroidal anti-inflammatory drugs (NSAIDs) and also showed high use of antiulcer PPI. CONCLUSIONS: There is a statistically significant correlation between physicians who generate lower pharmaceutical expenditure and have a higher quality of prescription. The most influencing factors in the pharmaceutical expenditure are a high percentage of pensioners in the medical quota, the use of novel drugs that do not provide therapeutic improvements and the prescription of statins and anti-ulcer PPI drugs
Asunto(s)
Humanos , Masculino , Femenino , Persona de Mediana Edad , Anciano , Prescripciones de Medicamentos/economía , Gastos en Salud/normas , Atención Primaria de Salud/normas , Calidad de la Atención de Salud , Antiinflamatorios no Esteroideos/economía , Antiulcerosos/economía , Farmacias , Atención Primaria de Salud/economía , Inhibidores de la Bomba de Protones/economía , Análisis de Regresión , Estudios Retrospectivos , Inhibidores de Hidroximetilglutaril-CoA Reductasas/economía , Modelos LogísticosRESUMEN
BACKGROUND: Proton pump inhibitors (PPIs) remain one of the world's most frequently prescribed medications and there is a growing number of publications on correct versus incorrect use of PPIs worldwide. The objective of this observational retrospective study was to assess changes in PPI prescribing trends over the past decade and pharmacists' effect on optimizing PPI prescribing practice at a tertiary hospital in China. METHODS: We collected the prescriptions of PPIs in our hospital from January 2007 to December 2016. Then the rate of PPI prescribing, the defined daily doses (DDDs) and expenditures were calculated and plotted to show the change in utilization of and expenditure on PPIs. Reasons behind this change and effect of pharmacists' intervention were evaluated by investigating the rationality of PPI use through sample surveys of patients of pre-intervention (Jul.-Dec. 2015) and post-intervention (Jul.-Dec. 2016). RESULTS: In outpatient settings, the rate of PPI prescribing remained almost constant, utilization (from 135,808 DDDs to 722,943 DDDs) and expenditure (from 1.85 million CNY to 7.96 million CNY) increased for the past ten years, dominated by oral formulations and rabeprazole. In contrast, in inpatient settings, the rate of PPI prescribing (from 20.41 to 37.21%), utilization (from 132,329 DDDs to 827,747 DDDs) and expenditure (from 3.15 million CNY to 25.29 million CNY) increased from 2007 to 2015 and then decreased, dominated by injection formulations and omeprazole. Pharmacist interventions could significantly promote the rational use of PPIs (44.00% versus 26.67%), decrease PPI use and reduce patients' charges (P < 0.05). CONCLUSIONS: The utilization of and expenditure on PPIs grew due to the increase of patients and irrational use of PPI. Pharmacist interventions help to reduce PPI utilization and expenditure and enhance rationality for inpatients, but much work should be done to regulate injection and originator formulas, and improve the rationality in the future.
Asunto(s)
Prescripciones de Medicamentos/economía , Reflujo Gastroesofágico/tratamiento farmacológico , Farmacéuticos , Pautas de la Práctica en Medicina/tendencias , Inhibidores de la Bomba de Protones/uso terapéutico , Centros de Atención Terciaria , China , Utilización de Medicamentos , Reflujo Gastroesofágico/economía , Humanos , Pacientes Internos , Pacientes Ambulatorios , Pautas de la Práctica en Medicina/estadística & datos numéricos , Inhibidores de la Bomba de Protones/economía , Estudios RetrospectivosRESUMEN
The introduction of proton-pump inhibitors (PPIs) into clinical practice since about thirty years has greatly improved our therapeutic approach to acid-related diseases for their well recognized efficacy and safety. Accordingly, the role of surgery has been enormously reduced in this field. The main indications for PPI use are universally acknowledged by many scientific societies and are the following: treatment of gastroesophageal reflux disease in its various forms and complications, eradication of H. pylori infection in combination with two or more antibiotics, therapy of H. pylori-negative peptic ulcers, healing and prevention of NSAID-associated gastric ulcers, co-therapy with endoscopic procedures to control upper digestive bleeding and medical treatment of Zollinger-Ellison Syndrome. Despite the above well-defined indications, however, the use of PPIs continues to grow every year in both Western and Eastern countries and this phenomenon poses serious queries about the appropriate prescription of these drugs worldwide. In fact, the endless expansion of PPI market has created important problems for many regulatory authorities for two relevant features: the progressive and irreversible increase of the costs of therapy with this class of drugs and the greater potential harms for the patients. So, there is the need for a reappraisal of PPI correct indications for both general practitioners and various specialists in order to re-establish a correct use of these effective drugs in daily clinical practice, according to the best evidence-based guidelines.
Asunto(s)
Inhibidores de la Bomba de Protones/uso terapéutico , Antiinflamatorios no Esteroideos/efectos adversos , Terapia Combinada , Quimioterapia Combinada , Esofagitis/tratamiento farmacológico , Medicina Basada en la Evidencia , Reflujo Gastroesofágico/tratamiento farmacológico , Infecciones por Helicobacter/tratamiento farmacológico , Antagonistas de los Receptores H2 de la Histamina/administración & dosificación , Humanos , Prescripción Inadecuada , Úlcera Péptica/tratamiento farmacológico , Úlcera Péptica/prevención & control , Guías de Práctica Clínica como Asunto , Uso Excesivo de Medicamentos Recetados , Inhibidores de la Bomba de Protones/administración & dosificación , Inhibidores de la Bomba de Protones/efectos adversos , Inhibidores de la Bomba de Protones/economíaRESUMEN
Stress ulcer prophylaxis (SUP) is often inappropriately utilized, particularly in critically ill patients. The objective of this study is to find an effective way of reducing inappropriate SUP use in an academic medical intensive care unit (ICU). Medical ICU patients receiving SUP were identified over a 1-month period, and their charts were reviewed to determine whether American Society of Health-System Pharmacists guidelines were followed. Inappropriate usage was calculated as inappropriate patient-days and converted to incidence per 100 patient-days. Two interventions were implemented: (1) Pharmacists reviewed indications for SUP on each patient during daily team rounds and daily medication reconciliation and (2) residents rotating on ICU services were educated on a bimonthly basis. Postintervention data were obtained in a similar fashion. Prior to intervention, the incidence of inappropriate SUP usage was calculated to be 26.75 per 100 patient-days (n = 1099 total patient-days). Total cost attributable to the inappropriate use was $2433. Post intervention, we were able to decrease the inappropriate incidence of SUP usage to 7.14 per 100 patient-days (n = 1149 total patient-days). In addition, total cost of inappropriate use was reduced to $239.80. Our study highlights an effective multidisciplinary approach to reduce the inappropriate use of SUP in an academic medical ICU. We were able to reduce the incidence of inappropriate use of SUP by 73.31% ( P < .001). Furthermore, we were able to decrease the costs by approximately $2200/month.